Pulse Biosciences (PLSE) Sets New 12-Month Low at $10.29

Pulse Biosciences Inc (NASDAQ:PLSE) shares hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $10.29 and last traded at $10.42, with a volume of 598 shares traded. The stock had previously closed at $10.81.

PLSE has been the subject of several research reports. ValuEngine upgraded Pulse Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, September 13th. BidaskClub upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday, July 4th.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Tuesday, July 31st. The company reported ($0.54) earnings per share for the quarter.

A number of institutional investors and hedge funds have recently modified their holdings of PLSE. Bank of America Corp DE raised its holdings in Pulse Biosciences by 631.2% in the 2nd quarter. Bank of America Corp DE now owns 16,101 shares of the company’s stock valued at $244,000 after acquiring an additional 13,899 shares during the last quarter. Silverleafe Capital Partners LLC acquired a new position in Pulse Biosciences in the 2nd quarter valued at $500,000. Bank of New York Mellon Corp raised its holdings in Pulse Biosciences by 9.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 61,550 shares of the company’s stock valued at $932,000 after acquiring an additional 5,127 shares during the last quarter. Northern Trust Corp raised its holdings in Pulse Biosciences by 15.3% in the 2nd quarter. Northern Trust Corp now owns 107,326 shares of the company’s stock valued at $1,625,000 after acquiring an additional 14,231 shares during the last quarter. Finally, BlackRock Inc. raised its holdings in Pulse Biosciences by 23.0% in the 2nd quarter. BlackRock Inc. now owns 600,109 shares of the company’s stock valued at $9,085,000 after acquiring an additional 112,061 shares during the last quarter. Institutional investors own 9.84% of the company’s stock.

Pulse Biosciences Company Profile (NASDAQ:PLSE)

Pulse Biosciences, Inc, a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications.

Recommended Story: How accurate is the Rule of 72?

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply